SCHEMBL25207133

SCHEMBL25207133

CCc1cc2c(cc1N)CCN(C(=O)C(F)(F)F)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 5/20 0.54
▸ ESR2 Q92731 5/20 0.54
▸ PKM P14618 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ NR1H2 P55055 1/20 0.39
▸ ABHD6 Q9BV23 4/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ TAAR1 Q96RJ0 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25207712 1.00 ESR1 (0.54) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL30411421 1.00 ESR1 (0.54) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL25207827 0.90 ESR1 (0.43) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL31164724 0.82 ESR1 (0.62) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL25226305 0.82 ESR1 (0.58) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL22782361 0.82 ESR1 (0.60) ESR1ESR2ABHD6NPC1KDM4E
SCHEMBL22782330 0.82 ESR1 (0.60) ESR1ESR2ABHD6NPC1KDM4E
SCHEMBL25204649 0.81 ESR1 (0.60) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL25205406 0.81 ESR1 (0.57) ESR1ESR2PKMHDAC8HDAC6
SCHEMBL30411869 0.81 ESR1 (0.60) ESR1ESR2PKMHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. 2025-05-08 — — US disclosed
EP-4433059-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF Erasca, Inc. (US) 2024-09-25 — — EP disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023215494-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-11-09 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed
WO-2023087027-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ERASCA, INC. (US) 2023-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250144094-A1 THIOPHENE ULK1/2 INHIBITORS AND THEIR USE THEREOF ULK1, ULK2, ULK3 ESR1 3000/4885ESR2 2354/4885PKM 2291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback